David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...